摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-溴-3-硝基-4-甲基吡啶 | 23056-45-3

中文名称
2-溴-3-硝基-4-甲基吡啶
中文别名
——
英文名称
2-bromo-4-methyl-3-nitropyridine
英文别名
2-bromo-3-nitro-4-methyl pyridine
2-溴-3-硝基-4-甲基吡啶化学式
CAS
23056-45-3
化学式
C6H5BrN2O2
mdl
MFCD04112527
分子量
217.022
InChiKey
LRYKMSPHPLXBHF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    263.3±35.0 °C(Predicted)
  • 密度:
    1.709±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.166
  • 拓扑面积:
    58.7
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 危险等级:
    IRRITANT
  • 危险品标志:
    Xi
  • 安全说明:
    S26,S37/39
  • 危险类别码:
    R20/21/22
  • 海关编码:
    2933399090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:199f11e2ad5b1586efeb37eb7f2415b5
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 2-Bromo-3-nitro-4-picoline
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 2-Bromo-3-nitro-4-picoline
CAS number: 23056-45-3

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H5BrN2O2
Molecular weight: 217

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • ENANTIOMERICALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF
    申请人:Soll Mark David
    公开号:US20100125089A1
    公开(公告)日:2010-05-20
    The present invention relates to novel aryloazol-2-yl-cyanoethylamino derivatives substantially enriched in an enantiomer of formula (I): and compounds of formula (IH) wherein R 3 , R 4 , R 5 , R 6 , R 7 , R 13a , R 13b , R 14a , R 14b , P, Q, V, W, X, Y, Z and a are as defined in the description, compositions thereof, processes for their preparation and their uses as pesticides.
    本发明涉及一种在式(I)的对映体方面显著富集的新颖芳基唑-2-基-氰基乙基氨基衍生物: 以及式(IH)的化合物 其中R3、R4、R5、R6、R7、R13a、R13b、R14a、R14b、P、Q、V、W、X、Y、Z和a如描述中所定义,以及它们的组合物、其制备方法以及它们作为杀虫剂的用途。
  • TGF BETA R ANTAGONISTS
    申请人:Bristol-Myers Squibb Company
    公开号:US20160176871A1
    公开(公告)日:2016-06-23
    The invention relates generally to compounds that modulate the activity of TGFβR-1 and TGFβR-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
    这项发明通常涉及调节TGFβR-1和TGFβR-2活性的化合物,包含这些化合物的药物组合物以及利用该发明的化合物治疗增殖性疾病和失调凋亡疾病(如癌症)的方法。
  • [EN] OGA INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS D'OGA
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:WO2019243533A1
    公开(公告)日:2019-12-26
    The present invention relates to O-GIcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations.
    本发明涉及O-GlcNAc水解酶(OGA)抑制剂。该发明还涉及包含这种化合物的药物组合物,制备这种化合物和组合物的方法,以及利用这种化合物和组合物预防和治疗抑制OGA有益的疾病,如tau病变,特别是阿尔茨海默病或进行性上核性麻痹症;以及伴有tau病理的神经退行性疾病,特别是由C90RF72突变引起的肌萎缩侧索硬化或颞叶前叶痴呆症。
  • Substituted fused pyrazolo compounds
    申请人:Zeneca Limited
    公开号:US05300478A1
    公开(公告)日:1994-04-05
    Novel substituted pyrazolo-rings fused to nitrogen containing heterocyclic rings having the following formula ##STR1## in which at least one of Y, Z or W is N or N-O and the remainder of Y, Z or W is C-R wherein the variables are as defined in the specification; and agriculturally acceptable salts thereof.
    将取代的嘧啶并入含氮杂环环的新型化合物,具有以下化学式##STR1## 其中至少有一个Y、Z或W是N或N-O,其余的Y、Z或W是C-R,其中变量如规范中定义;以及其农业上可接受的盐。
  • 具有蒽环和吡啶并吲哚环结构的化合物及含该化合物的有机发光二极管器件
    申请人:北京拓彩光电科技有限公司
    公开号:CN109761981A
    公开(公告)日:2019-05-17
    本发明涉及一种被取代了的蒽环和吡啶并吲哚环结构化合物和一种有机发光二极管(OLED)器件,更具体而言,涉及一种优异性能的被取代了的蒽环和吡啶并吲哚环结构化合物和使用该化合物的OLED器件。该有机电致发光器件具有一对电极和其间夹持的至少一层有机层。其中下述通式1通式2所示的被取代了的蒽环和吡啶并吲哚环结构化合物被用作至少一个所述的有机层的构成材料。
查看更多